XML 213 R81.htm IDEA: XBRL DOCUMENT v3.25.0.1
Revenue recognition - Collaboration and Royalty Revenue (Details)
$ in Thousands
1 Months Ended 12 Months Ended
Sep. 30, 2022
USD ($)
Dec. 31, 2024
USD ($)
product
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Nov. 30, 2011
USD ($)
Revenue recognition          
Number of approved products | product   2      
Remaining potential milestones that can be achieved   $ 150,000      
Revenue   806,780 $ 937,822 $ 698,801  
Collaboration revenue          
Revenue recognition          
Revenue   304 100,030 50,052  
Royalty revenue          
Revenue recognition          
Revenue   $ 203,864 168,856 113,521  
SMA License Agreement          
Revenue recognition          
Number of approved products | product   1      
SMA License Agreement | Collaboration revenue          
Revenue recognition          
Revenue     100,000 50,100  
SMA License Agreement | Royalty revenue          
Revenue recognition          
Revenue   $ 203,900 168,900 $ 113,500  
Research And Development Event Milestones | SMA License Agreement          
Revenue recognition          
Remaining potential milestones that can be achieved   0      
Sales Milestones | SMA License Agreement          
Revenue recognition          
Remaining potential milestones that can be achieved   $ 150,000      
Net sales milestone threshold achieved $ 750,000   1,500,000    
Sales Milestones | SMA License Agreement | Prepaids and other current assets          
Revenue recognition          
Milestone payments due $ 50,000   $ 100,000    
Maximum | Research And Development Event Milestones | SMA License Agreement | Roche          
Revenue recognition          
Remaining potential milestones that can be achieved         $ 135,000
Maximum | Sales Milestones | SMA License Agreement | Roche          
Revenue recognition          
Remaining potential milestones that can be achieved         $ 325,000